ADVERTISEMENT
ADVERTISEMENT

Stem Cell Approvals Are Up

The number of human embryonic stem cells approved for federal funding continues to grow.

Jef Akst
Jef Akst

Jef Akst is managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.

View full profile.


Learn about our editorial policies.

WIKIMEDIA COMMONS, NISSIM BENVENISTY

Despite the recent legal battles, the National Institutes of Health continues to approve new human embryonic stem cells (hESC) lines for federal funding. Last month, the agency  approved 37 new hESC lines—more than any other month this year. There are now a total of 128 lines currently approved for federal funding—up from just 20 approved lines prior to President Barack Obama’s 2009 executive order to loosen stem cell regulations—with 37 more pending review.

The field’s exponential growth since the early part of the century is suggestive that it may one day rival the $300 billion prescription-drug market, Mark Monane, a Needham & Co. analyst, told Bloomberg. Though the industry is riddled with “sociopolitical risk,” he said, there is “a real opportunity to see if embryonic stem cells are going to work.”

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
ADVERTISEMENT